冨田 章裕

Medicine & Life Sciences

1. Myelodysplastic Syndromes 100%
2. Rituximab 96%
3. B-Cell Lymphoma 88%
4. Lymphoma 73%
5. Acute Myeloid Leukemia 53%
6. Lymphoma, Large B-Cell, Diffuse 47%
7. Mutation 43%
8. Thyroid Hormone Receptors 43%
9. Co-Repressor Proteins 42%
10. DNA 39%
11. Japan 36%
12. Thyroid Hormones 35%
13. Leukemia 35%
14. Genes 33%
15. Acetylation 33%
16. Cell-Free Nucleic Acids 33%
17. Proteins 31%
18. Neoplasms 28%
19. Hodgkin Disease 28%
20. Acute Promyelocytic Leukemia 28%
21. Hematology 28%
22. Survival 27%
23. Multicenter Studies 26%
24. Azacitidine 24%
25. Histones 24%
26. pembrolizumab 24%
27. Apoptosis 24%
28. Retrospective Studies 24%
29. Hemosiderin 23%
30. Methylation 23%
31. Arsenic Trioxide 23%
32. Bortezomib 23%
33. B-Lymphocytes 22%
34. Therapeutics 22%
35. Anura 22%
36. Epigenomics 22%
37. T-Lymphocytes 21%
38. Lymphoproliferative Disorders 21%
39. Safety 21%
40. Myeloid Cells 20%
41. ravulizumab 19%
42. Human Herpesvirus 4 19%
43. asciminib 18%
44. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18%
45. Ferritins 18%
46. Chromatin 18%
47. Drug Therapy 17%
48. Non-Hodgkin's Lymphoma 17%
49. Decitabine 17%
50. Protein-Tyrosine Kinases 16%